BRCA1 and triple-negative breast carcinoma: Third, preclinical and clinical studies have suggested that PARP inhibitors are particularly effective in tumors that have deleterious mutations in HR pathway genes such as BRCA1 and BRCA2. In contrast, tumors such as triple negative breast cancer that have BRCA1/2 gene methylation appear to be less sensitive.